Objective: N-terminal probrain natriuretic peptide (NT-proBNP) is a biomarker of interest in many cardiopulmonary diseases in extremely low birth weight (ELBW) Infants. However, there is a gap in knowledge about the trend of ELBW infant's urinary NT-proBNP during the neonatal period.
Aim: To determine the trend of urinary NT-proBNP during the first 4 weeks of life of an ELBW infant.
Study Design: We analyzed prospectively enrolled 87 ELBW infants. Urinary NT-proBNP to creatinine ratios were measured on days 1 to 7, 14, and 28 of life. We plotted each study point's means to determine the trend of urinary NT-proBNP over the entire neonatal period. Data were analyzed using the Friedman analysis of variance for comparative analysis of study points.
Results: Urinary NT-proBNP/creatinine ratios were significantly elevated on days 1 to 7 (mean 2,452, ± 1,518) than day 14 (mean 747, ± 176), and day 28 (mean 149, ± 54), = 0.001. Overall, urinary NT-proBNP levels were highest during days 1 to 3 (mean 3,232, ± 1,255) and lowest on day 28 (mean 149, ± 54).
Conclusion: Urinary NT-proBNP levels are higher during the first week in ELBW infants with a downward trend during the neonatal period, the lowest values at 4 weeks postnatal age. More studies are required to determine the clinical utility of this trend during and beyond the neonatal period.
Key Points: · NT-proBNP is a biomarker for monitoring cardiac disease in premature infants.. · The trend of urinary NT-proBNP is unknown in premature infants.. · A trend of urinary NT-proBNP was determined during the first 4 weeks in premature infants..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1692-1039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world.
Sci Rep
December 2024
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are the only medications that improve clinical outcomes regardless of baseline left ventricular ejection fraction. Despite the recognized effectiveness of SGLT-2 inhibitors, there remains a paucity of research on the discontinuation of these medications. The objective of this study is to analyze the rate of discontinuation of SGLT-2 inhibitors, to evaluate the impact of discontinuation on the clinical outcome, and to identify the factors associated with discontinuation.
View Article and Find Full Text PDFA Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.
Am J Cardiovasc Drugs
December 2024
Office of Human Research, Memorial Healthcare System, Hollywood, FL, 33021, USA.
Article Synopsis
- Sodium-glucose cotransporter 2 inhibitors (SGLT2is) show promise as a treatment for heart failure (HF) in adults with adult congenital heart disease (ACHD), but more research is needed.
- A systematic review and meta-analysis of eight studies with 287 patients indicated that SGLT2is improved functional class and reduced NT-proBNP levels, along with a decrease in systolic blood pressure.
- The medications were generally well tolerated, with minor side effects reported, but there were no serious complications like hypoglycemia or ketoacidosis, highlighting the need for further large-scale studies to verify these findings.
Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study.
Ther Adv Cardiovasc Dis
November 2024
Cardiology and Cardiovascular Pathophysiology, S. Maria Della Misericordia Hospital, University of Perugia, Perugia, Italy.
Background: Sacubitril/valsartan (S/V) is a cornerstone treatment for heart failure (HF). Beneficial effects on hospitalization rates, mortality, and left ventricular remodeling have been observed in patients with heart failure and reduced ejection fraction (HFrEF). Despite the positive results, the influence of S/V on renal function during long-term follow-up has received little attention.
View Article and Find Full Text PDFSerum and urinary 5-hydroxyindolacetic acid, serotonin, chromogranin A, and NT-proBNP for the detection of carcinoid heart disease.
Eur J Endocrinol
November 2024
Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, Bron 69500, France.
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.
(Prote)omics for Superior Management of Kidney and Cardiovascular Disease-A Thought-Provoking Impulse From Nephrology.
Proteomics
November 2024
Medical Headquarter, Kuratorium for Dialysis and Transplantation, Neu-Isenburg, Germany.
Chronic kidney disease (CKD) and cardiovascular disease (CVD) are complex conditions often managed by nephrologists. This viewpoint paper advocates for a multi-omics approach, integrating clinical symptom patterns, non-invasive biomarkers, imaging and invasive diagnostics to enhance diagnosis and treatment. Early detection of molecular changes, particularly in collagen turnover, is crucial for preventing disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!